- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04323722
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer (MESORECT-VV)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to show that the variations of bladder volume and mesorectal movements are less with empty versus filled bladder in rectal cancer.
In this study, patient will be treated with 3D conformal radiotherapy (3D-CRT) radiotherapy with a filled bladder condition, as per standard care, in supine position. A total dose of 45 or 50 Gy in 25 fractions, 5 fractions per week is received.
A Chest, abdomen and pelvis imaging will be performed before treatment start. Patients receive planning CT scan with filled bladder and then with empty bladder on the same day. Only planning CT scan with filled bladder will be used patient treatment.
During radiotherapy treatment, patient will receive CBCTs with filled ans empty bladder on Day 1 ; 2 and 3 on the first week and once a week after.
Multiple parameters will be assessed before treatment (using planning CT scan) and during radiotherapy treatment (CBCTs) in empty ans filled bladder conditions : Bladder volume, mesorectal movements.
A dosimetric study will be performed in Intensity-modulated radiotherapy (IMRT) in empty and filled bladder conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Emmanuel RIO, MD
- Phone Number: +33240679900
- Email: emmanuel.rio@ico.unicancer.fr
Study Contact Backup
- Name: Nadia ALLAM, PHD
- Phone Number: +33240679826
- Email: nadia.allam@ico.unicancer.fr
Study Locations
-
-
-
Angers, France, 49055
- Recruiting
- Institut de Cacerologie de l'ouest - site Paul Papin
-
Contact:
- Amaury Paumier, MD
- Phone Number: +33241352700
- Email: Amaury.Paumier@ico.unicancer.fr
-
Saint-Herblain, France, 44805
- Recruiting
- ICO René Gauducheau
-
Contact:
- Emmanuel RIO, MD
- Phone Number: +33240679900
- Email: emmanuel.rio@ico.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed rectal adenocarcinoma
- T2 N+ or T3 any N, eligible for radiotherapy or neo-adjuvant radio-chemotherapy treatment in a long course of 25 fractions
- Performance Status less or equal to 2
- Male or female 18 Years and older
- Creatinine clearance greater than or equal to 50ml/min
- Fertile patients must use effective contraception
- Written informed consent
- Patient must be affiliated to a Social Health Insurance
Exclusion Criteria:
- Previous treatment with pelvic radiotherapy
- Chronic inflammatory bowel disease in flare-up.
- Urinary catheterization, urinary diversion or cystectomy
- Hip prosthesis
- History of prostatectomy, or hysterectomy
- Urinary incontinence > 2
- Pregnant or nursing patient
- Persons deprived of their liberty, as well as adults subject to a legal protection measure
- Impossibility to submit to the medical follow-up of this clinical trial for geographical, social or psychological reasons
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Empty bladder
Planning CT scan and CBCTs with empty bladder after standard Planning CT scan and CBCTs with filling bladder
|
Patient will receive a Planning CT scan, 3 CBCTs on the first week and once a week during radiotherapy treatment with an Empty Bladder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate using imaging techniques and dosimetric analysis the performance of empty versus filled bladder radiotherapy treatment
Time Frame: 3.5 years
|
Throughout the radiotherapy treatment, the reproducibility of positioning of the anterior surface of mesorectum will be assessed with empty and filled bladder
|
3.5 years
|
Evaluate using imaging techniques and dosimetric analysis the performance of empty versus filled bladder radiotherapy treatment
Time Frame: 3.5 years
|
Throughout the radiotherapy treatment, the reliability of positioning of the anterior surface of mesorectum will be assessed with empty and filled bladder
|
3.5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate mesorectal movements during radiotherapy in empty versus filled bladder
Time Frame: 3.5 years
|
Compare mesorectal movements during radiotherapy treatment compared to the planning CT scan in the case of a filled versus an empty bladder
|
3.5 years
|
Evaluate changes in bladder volume during radiotherapy in empty versus filled bladder
Time Frame: 3.5 years
|
Compare changes in bladder volume during treatment versus planning CT scan for filled bladder versus empty bladder
|
3.5 years
|
IMRT (Intensity-Modulated Radiotherapy) dosimetric study in patients with filled or empty bladder
Time Frame: 3.5 years
|
Compare and validate (in silico on planning CT scan) the compliance with dose constraints to organs-at-risk in patients with filled or empty bladder in IMRT
|
3.5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICO-2019-15
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
Clinical Trials on Empty Bladder planning CT scan and CBCTs
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
Royal Marsden NHS Foundation TrustInstitute of Cancer Research, United KingdomUnknown
-
University of LouisvilleJames Graham Brown Cancer CenterActive, not recruitingLung CancerUnited States
-
AHS Cancer Control AlbertaCalgary Health RegionUnknownLung Neoplasms | Positron Emission TomographyCanada
-
Ontario Clinical Oncology Group (OCOG)Ontario Ministry of Health and Long Term CareCompletedAdenocarcinoma | Cervical Cancer | Squamous Cell Carcinoma | Adenosquamous CarcinomaCanada
-
Ohio State University Comprehensive Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ZurichSwiss National Science Foundation; Balgrist University HospitalCompletedMultiple Sclerosis | Overactive Bladder | Spinal Cord Injury | Neurogenic Lower Urinary Tract DysfunctionSwitzerland
-
University of UtahNational Cancer Institute (NCI)CompletedFluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated VenothromboembolismVenothromboembolismUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)SuspendedMalignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Refractory Sclerodermatous Graft Versus Host DiseaseUnited States
-
Royal Marsden NHS Foundation TrustRecruitingSolid Tumor, AdultUnited Kingdom